-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
-
Summary
-
Landos Biopharma, Inc. quarterly Additional Paid in Capital history and growth rate from Q4 2020 to Q1 2024.
- Landos Biopharma, Inc. Additional Paid in Capital for the quarter ending March 31, 2024 was $187M, a 0.69% increase year-over-year.
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Growth (%)